TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap

Executive Summary

• TempraMed announced the publication of a peer‑reviewed case report demonstrating that its VIVI Cap™ device provides passive thermal protection for insulin during high‑temperature travel.
• The single‑patient data showed improved glycemic metrics (time‑in‑range 86% vs. 82%) and reduced episodes of hyperglycemia without any emergency visits.
• The paper also cites independent validation of TempraMed’s payer ROI model, reinforcing the economic case for reimbursement discussions with health insurers.

Key Details

• Publication: “Passive Thermal Protection of In‑Use Insulin During Summer Travel: Device Description and Single‑Patient Case Report with a Simple Cost Perspective,” Journal of Clinical & Medical Case Reports (Feb 2026).
• Clinical Findings (single patient, Greece, ambient 35‑38 °C):
• Time‑in‑range increased to 86% (vs. 82% without VIVI Cap).
• Time above 250 mg/dL reduced to 3% (vs. 5%).
• Mealtime insulin dose remained stable despite extreme heat.
• No emergency department or urgent care visits recorded.
• Patient‑reported outcomes: Lower anxiety, higher confidence in insulin efficacy under hot conditions.
• Economic Validation: The case report references TempraMed’s independently validated payer ROI model (validated by the Validation Institute through Jan 2027), highlighting cost savings from:
• Prevention of medication wastage due to suspected temperature excursions.
• Avoidance of heat‑related glycemic deterioration and related emergency events.
• Reduced anxiety‑driven healthcare utilization.
• Management Commentary: CEO Ron Nagar emphasized that the clinical evidence provides scientific context to the already validated economic model, strengthening reimbursement discussions.
• Strategic Implications: TempraMed views the publication as a bridge between clinical plausibility and health‑economic validation, supporting pilot programs, payer coverage decisions, and positioning VIVI Cap™ as a reimbursable standard for diabetes management and other temperature‑sensitive therapies.

Notable Quotes

“This publication provides scientific context to the economic case we have already validated,” said Ron Nagar, CEO of TempraMed. “It highlights how thermal protection can translate into clinical stability and patient confidence in high‑risk environments—exactly the drivers incorporated into our validated payer ROI model.”